Corvus Pharmaceuticals Inc., of Burlingame, Calif., reported interim results from its phase I/Ib study, showing that treatment with CPI-444 as a single agent and in combination with Tecentriq (atezolizumab, Roche Holding AG) was well-tolerated and resulted in antitumor activity in patients with multiple types of advanced solid tumors, including those resistant or refractory to prior treatment with anti-PD-1 or anti-PD-L1 antibodies.